Urodynamic effects of dutasteride add‐on therapy to alpha‐adrenergic antagonist for patients with benign prostatic enlargement: Prospective pressure‐flow study

Abstract

Dutasteride can improve lower urinary tract symptoms by improving storage bladder function and relieving obstruction.

Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open‐label, controlled trial (DIrecT Study)

“…Also, in the combination study with propiverine, it is thought that the addition of propiverine shows almost the same reduction effect of storage symptoms as the present study . Reduction of the PV was similar between the groups, and similar to that previously reported with an α 1 ‐blocker in combination with dutasteride …”

Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement

“…In accordance with previous reports, the present study confirmed that 24‐week treatment of dutasteride reduced prostate size and improved voiding and storage symptoms including urinary urgency. We previously examined urodynamic effects of dutasteride on BOO and bladder storage function and showed that dutasteride relieved obstruction and improved bladder storage function . The present study confirmed the beneficial effect of dutasteride in relieving obstruction and improving bladder storage function.…”

Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors

“…Wada et al [32] studied the effect in 52 patients receiving dutasteride, in addition to alpha-adrenergic antagonists, if they were not satisfied with their treatment. The authors concluded that long-term dutasteride administration as the adjunct therapy resulted in moderate improvement of the obstructive symptoms.…”

“…Twenty-three articles of highest reliability (inclusion criteria was maximal level of evidence) were selected, 6 of which were dedicated to the monotherapy with PDE5 inhibitors in patients with BPH-LUTS and concurrent BPH-LUTS and ED [18–23]; 4 articles reported monotherapy with alpha-adrenergic antagonists in patients with BPH-LUTS [24–27]; 5 were dedicated to monotherapy with 5-alpha reductase inhibitors in men with BPH-LUTS [28–32]; 7 reported combined therapy with alpha-adrenergic antagonists and PDE5 inhibitors in patients with BPH-LUTS [33–39]; 1 reported combined therapy with alpha-adrenergic antagonists and 5-alpha reductase inhibitors in patients with BPH-LUTS [40]. Thirty-one articles – retrospective works, clinical cases and low reliability publications were excluded from the analysis.…”